NCT02003222进行中（未招募）3 期
A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia in Adults
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 进行中（未招募）
- 入组人数
- 488
- 试验地点
- 544
- 主要终点
- Overall Survival (OS) Among Patients Who Were MRD Negative After Induction and Intensification Chemotherapy
研究概览
简要总结
This randomized phase III trial studies combination chemotherapy with blinatumomab to see how well it works compared to induction chemotherapy alone in treating patients with newly diagnosed breakpoint cluster region (BCR)-c-abl oncogene 1, non-receptor tyrosine kinase (ABL)-negative B lineage acute lymphoblastic leukemia. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as blinatumomab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. It is not yet known whether combination chemotherapy is more effective with or without blinatumomab in treating newly diagnosed acute lymphoblastic leukemia.
详细描述
PRIMARY OBJECTIVE:
I. To compare the overall survival (OS) of blinatumomab in conjunction with chemotherapy to chemotherapy alone in patients with BCR-ABL-negative B cell precursor acute lymphoblastic leukemia (ALL) who are minimal residual disease (MRD) negative after induction and intensification chemotherapy, based on multiparameter flow cytometric (MFC) assessment of residual blasts.
SECONDARY OBJECTIVES:
I. To compare the relapse-free survival (RFS) of blinatumomab in conjunction with chemotherapy to chemotherapy alone in MRD negative patients after induction and intensification chemotherapy.
II. To compare the OS and RFS of those patients who are MRD positive (+) at step 3 randomization/registration and then convert to MRD negative (-) after 2 cycles of blinatumomab to those patients who are MRD- at randomization and remain MRD- after 2 cycles of blinatumomab or consolidation chemotherapy.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 30 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •PRE-REGISTRATION
- •Diagnostic bone marrow and/or peripheral blood specimens must be submitted for immunophenotyping and selected molecular testing, and the establishment of BCR/ABL status; testing will be performed by the Eastern Cooperative Oncology Group (ECOG)-American College of Radiation Imaging Network (ACRIN) Leukemia Translational Research Laboratory (LTRL) and reported to the institution
- •NOTE: IT IS ESSENTIAL THAT A SAMPLE CONTAINING SUFFICIENT BLAST CELLS BE SUBMITTED TO THE ECOG-ACRIN LTRL AT BASELINE SO THAT SUBSEQUENT BONE MARROW ASSESSMENTS OF MRD CAN BE DONE; IN ADDITION TO ALLOWING THE LTRL TO CONFIRM ELIGIBILITY BASED ON BLAST CELL IMMUNOPHENOTYPE AND BCR/ABL STATUS, IT IS ALSO IMPERATIVE THAT AN ADEQUATE NUMBER OF BLASTS BE BANKED FOR ANALYSIS BY DRS MULLIGHAN/WILLMAN. WITHOUT ADEQUATE BASELINE SAMPLES, PATIENTS WILL NOT BE ABLE TO BE TREATED AND RANDOMIZED ON THIS PROTOCOL; IF A BONE MARROW ASPIRATE IS NOT AVAILABLE FOR LTRL SUBMISSION AT BASELINE, IT IS IMPERATIVE THAT DR PAIETTA FROM THE LTRL IS CALLED TO DISCUSS THE PERIPHERAL BLOOD WHITE BLOOD CELL (WBC) AND BLAST COUNT BEFORE BLOOD ONLY IS SUBMITTED
- •NOTE: Hydroxyurea can be given for up to 5 days prior to initiation of protocol therapy for control of leukocyte count and/or other symptoms or signs; corticosteroids can be given after pre-registration to the protocol and submission of baseline marrow and blood samples for control of leukocyte count and/or other symptoms or signs prior to initiation of protocol therapy if needed; if corticosteroids are given prior to pre-registration, contact the study chair as the patient may still be eligible to participate
- •INDUCTION ELIGIBILITY CRITERIA-STEP 1
- •Age >= 30 years and =< 70 years
- •New diagnosis of B lineage ALL must be made upon bone marrow or peripheral blood immunophenotyping; cases with myeloid antigen expression, but unequivocal lymphoid immunophenotype, are eligible
- •Negativity for the Philadelphia chromosome must be established by conventional cytogenetics, fluorescence in situ hybridization (FISH) and/or polymerase chain reaction (PCR); patients who are negative for the Philadelphia chromosome by conventional cytogenetics must have FISH or PCR performed for BCR/ABL to exclude occult translocations
- •Cytogenetic analysis must be performed from diagnostic bone marrow (preferred) or if adequate number of circulating blasts from peripheral blood; FISH testing for common B-lineage ALL abnormalities including t(9;22) (BCR/ABL1), t(12;21) (ETS-variant gene 6 [ETV6]/runt-related transcription factor 1 [RUNX1]), t(1;19) (pre-B-cell leukemia homeobox 1 [PBX1]/transcription factor 3 [TCF3]), +4,+10,+17, (centromeric [Cen]4/Cen10/Cen17), t(11q23;var), (myeloid/lymphoid or mixed lineage leukemia [MLL]), deletion (del)(9p) (cyclin-dependent kinase inhibitor 2A [CDKN2A]/Cen9), and t(14;var) (immunoglobulin heavy chain [IGH] is encouraged); if there are few or no circulating blasts and an adequate marrow sample cannot be obtained for cytogenetic analysis, the patient may still enroll on the trial
- •Serum direct bilirubin < 2 mg/dl or serum total bilirubin =< 3 (obtained =< 48 hours prior to registration); NOTE: the above stipulation for normal hepatic function does not apply if liver dysfunction is due to leukemia infiltration
- •Serum creatinine < 2 mg/dl (obtained =< 48 hours prior to registration); NOTE: the above stipulation for normal hepatic function does not apply if liver dysfunction is due to leukemia infiltration
- •Patient should be human leukocyte antigen (HLA) typed (A, B, C, DR and DQ) during induction therapy phase or a written explanation for not undergoing HLA typing on the flow sheet
- •Patients with known human immunodeficiency virus (HIV) infection are eligible if they meet all of the following criteria:
- •No history of acquired immune deficiency syndrome (AIDS)-related complications other than a history of low CD4+ T-cell count (< 200/mm^3) prior to initiation of combination antiretroviral therapy; on study CD4+ T-cell count may not be informative due to leukemia and should not be used as an exclusion criterion if low
- •Patient must be healthy on the basis of HIV disease with high likelihood of near normal life span were it not for the leukemia
- •Patient must have serum HIV viral load of < 200 copies/mm^3
- •Patient must be on combination antiretroviral therapy with minimal pharmacokinetic interactions with study therapy and minimal overlapping clinical toxicity with protocol therapy
- •Patient must not be receiving protease inhibitors or once daily formulations containing cobicistat, stavudine, or on regimens containing stavudine or zidovudine
- •It is recommended to utilize a regimen of the integrase inhibitor, dolutegravir, combined with either disoproxil fumarate/emtricitabine or dolutegravir combined with tenofovir alafenamide/emtricitabine
- •Patient must have no history of recent myocardial infarction (within three months), uncontrolled congestive heart failure, or uncontrolled cardiac arrhythmia
- •Patient must have a normal cardiac ejection fraction by pretreatment multigated acquisition scan (MUGA) or echocardiogram within 4 weeks prior to registration (resting ejection fraction >= 40% or >= 5% increase with exercise), shortening fraction by echocardiogram >= 24%, or to within the normal range of values for the institution
- •Women must not be pregnant or breast-feeding due to administration of teratogenic chemotherapy and must not become pregnant or breastfeed during protocol therapy and for at least 3 months after protocol therapy; woman of childbearing potential must abstain from sexual activity or be willing to use 2 highly effective forms of contraception throughout protocol therapy and for at least an additional 3 months after the last dose of protocol-specified therapy; all females of childbearing potential must have a blood test or urine study within 2 weeks prior to registration to rule out pregnancy; a female of childbearing potential is any woman, regardless of whether they have undergone tubal ligation, who meets the following criteria: has not undergone a hysterectomy or bilateral oophorectomy; or has not been naturally postmenopausal for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months)
- •Men who have a female partner of childbearing potential must be willing to use 2 highly effective forms of contraception throughout protocol therapy and for at least an additional 3 months after the last dose of protocol-specified therapy; men who have a pregnant partner must be willing to use a condom during sexual activity throughout protocol therapy and for 3 months after the last dose of protocol-specified therapy
- •ECOG performance score 0-3
- •Patient must have given written informed consent
- •POST-INDUCTION THERAPY ELIGIBILITY CRITERIA (PRIOR TO INTENSIFICATION-STEP 2)
- •ECOG performance status 0-2
- •Patients must have achieved a CR or CRi
- •Patients who have achieved a CR or CRi must have maintained peripheral blood evidence of a CR or CRi
- •Patient must be CNS (cerebrospinal fluid [CSF]) negative for leukemia
- •Patients must have resolved any serious infectious complications related to induction
- •Any significant medical complications related to induction must have resolved
- •Serum creatinine =< 2.0 mg/dl (obtained =< 48 hours prior to registration)
- •Serum direct bilirubin < 2 mg/dL or serum total bilirubin =< 3 (obtained =< 48 hours prior to registration)
- •Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 3 x upper limit of normal (ULN) (obtained =< 48 hours prior to registration)
- •RANDOMIZATION OR ASSIGNMENT TO BLINATUMOMAB OR NO BLINATUMOMAB-STEP 3
- •Patients must have an ECOG performance status of 0-2
- •Patients must have maintained peripheral blood evidence of a remission and must have a CR or CRi, confirmed on restaging bone marrow (BM) aspirate and biopsy
- •Patients must have resolved any serious infectious complications related to therapy
- •Any significant medical complications related to therapy must have resolved
- •Direct or total bilirubin < 1.5 x ULN (unless related to Gilbert's or Meulengracht's syndrome); the values must be obtained within 48 hours prior to randomization
- •Serum creatinine < 1.5 x ULN; the values must be obtained within 48 hours prior to randomization
- •Bone marrow aspirates must be submitted for centralized minimal residual disease (MRD) assessment performed by the ECOG-ACRIN Leukemia Translational Research Laboratory
- •MRD results will be reported to the submitting institution
- •NOTE: FOR MRD ASSESSMENTS, AN ASPIRATE FROM A SEPARATE BONE MARROW ASPIRATION SITE MUST BE SUBMITTED (THE NEEDLE CAN BE RE-DIRECTED THROUGH THE SAME SKIN PUNCTURE SITE); ONLY SUBMIT ASPIRATES FROM THE FIRST PULL OF AN ASPIRATION SITE FOR MRD TESTING; DO NOT SUBMIT SAMPLES FROM THE SECOND OR THIRD PULL OF THE SAME ASPIRATION SITE
- •In B-lineage ALL, MRD levels in peripheral blood or from a dilute marrow aspiration can be 300% lower, on average, than those in bone marrow at a given time point; submitting a first pull from a separate aspiration site will ensure that MRD determinations used in randomization and trial interpretation are accurate
- •NOTE: failure to submit bone marrow aspirates will result in a major violation at the time of an audit
- •CRITERIA FOR ALLOGENEIC TRANSPLANTATION
- •A suitable donor must be identified; there are no restrictions on donor type and can include a matched sibling, a matched or mismatched unrelated donor, a family haplotype matched donor or a cord blood donor (single or double)
- •Patients should meet the eligibility criteria for RANDOMIZATION OR ASSIGNMENT TO BLINATUMOMAB OR NO BLINATUMOMAB-STEP 3
- 另有 5 项未显示
排除标准
- •Mature B ALL (Burkitt's-like leukemia) is excluded from enrollment in this trial; pre-study bone marrow biopsy and aspirate must be completed =< 1 week prior to registration
- •Patient must not have a concurrent active malignancy for which they are receiving treatment
- •Patient must not have intercurrent organ damage or medical problems that will jeopardize the outcome of therapy (i.e., psychiatric disorder, drug abuse, pregnancy)
- •Patient must not have an antecedent hematologic disorder
- •Patient must not have a history or presence of clinically relevant central nervous system (CNS) pathology such as epilepsy, seizure, paresis, aphasia, stroke, severe brain injuries, dementia; Parkinson's disease, cerebellar disease, organic brain syndrome, psychosis, or other significant CNS abnormalities
- •Patient must not have an active uncontrolled infection
研究组 & 干预措施
Arm I (blinatumomab, chemotherapy)
Experimental
See Detailed Description
干预措施: Lumbar Puncture (Procedure)
Arm II (chemotherapy)
Active Comparator
See Detailed Description
干预措施: Allogeneic Hematopoietic Stem Cell Transplantation (Procedure)
Arm II (chemotherapy)
Active Comparator
See Detailed Description
干预措施: Bone Marrow Biopsy (Procedure)
Arm I (blinatumomab, chemotherapy)
Experimental
See Detailed Description
干预措施: Etoposide (Drug)
Arm II (chemotherapy)
Active Comparator
See Detailed Description
干预措施: Cyclophosphamide (Drug)
Arm I (blinatumomab, chemotherapy)
Experimental
See Detailed Description
干预措施: X-Ray Imaging (Procedure)
Arm II (chemotherapy)
Active Comparator
See Detailed Description
干预措施: Bone Marrow Aspiration (Procedure)
Arm I (blinatumomab, chemotherapy)
Experimental
See Detailed Description
干预措施: Rituximab (Biological)
Arm I (blinatumomab, chemotherapy)
Experimental
See Detailed Description
干预措施: Vincristine Sulfate (Drug)
Arm I (blinatumomab, chemotherapy)
Experimental
See Detailed Description
干预措施: Vincristine (Drug)
Arm II (chemotherapy)
Active Comparator
See Detailed Description
干预措施: Vincristine (Drug)
Arm I (blinatumomab, chemotherapy)
Experimental
See Detailed Description
干预措施: Blinatumomab (Biological)
Arm I (blinatumomab, chemotherapy)
Experimental
See Detailed Description
干预措施: Mercaptopurine (Drug)
Arm II (chemotherapy)
Active Comparator
See Detailed Description
干预措施: Lumbar Puncture (Procedure)
Arm II (chemotherapy)
Active Comparator
See Detailed Description
干预措施: X-Ray Imaging (Procedure)
Arm II (chemotherapy)
Active Comparator
See Detailed Description
干预措施: Mercaptopurine (Drug)
Arm II (chemotherapy)
Active Comparator
See Detailed Description
干预措施: Daunorubicin Hydrochloride (Drug)
Arm II (chemotherapy)
Active Comparator
See Detailed Description
干预措施: Vincristine Sulfate (Drug)
Arm II (chemotherapy)
Active Comparator
See Detailed Description
干预措施: Methotrexate (Drug)
Arm I (blinatumomab, chemotherapy)
Experimental
See Detailed Description
干预措施: Dexamethasone (Drug)
Arm I (blinatumomab, chemotherapy)
Experimental
See Detailed Description
干预措施: Allogeneic Hematopoietic Stem Cell Transplantation (Procedure)
Arm I (blinatumomab, chemotherapy)
Experimental
See Detailed Description
干预措施: Biospecimen Collection (Procedure)
Arm I (blinatumomab, chemotherapy)
Experimental
See Detailed Description
干预措施: Bone Marrow Aspiration (Procedure)
Arm I (blinatumomab, chemotherapy)
Experimental
See Detailed Description
干预措施: Bone Marrow Biopsy (Procedure)
Arm I (blinatumomab, chemotherapy)
Experimental
See Detailed Description
干预措施: Cytarabine (Drug)
Arm I (blinatumomab, chemotherapy)
Experimental
See Detailed Description
干预措施: Daunorubicin Hydrochloride (Drug)
Arm II (chemotherapy)
Active Comparator
See Detailed Description
干预措施: Biospecimen Collection (Procedure)
Arm II (chemotherapy)
Active Comparator
See Detailed Description
干预措施: Prednisone (Drug)
Arm II (chemotherapy)
Active Comparator
See Detailed Description
干预措施: Rituximab (Biological)
Arm I (blinatumomab, chemotherapy)
Experimental
See Detailed Description
干预措施: Prednisone (Drug)
Arm I (blinatumomab, chemotherapy)
Experimental
See Detailed Description
干预措施: Pegaspargase (Drug)
Arm II (chemotherapy)
Active Comparator
See Detailed Description
干预措施: Cytarabine (Drug)
Arm II (chemotherapy)
Active Comparator
See Detailed Description
干预措施: Daunorubicin (Drug)
Arm II (chemotherapy)
Active Comparator
See Detailed Description
干预措施: Pegaspargase (Drug)
Arm I (blinatumomab, chemotherapy)
Experimental
See Detailed Description
干预措施: Cyclophosphamide (Drug)
Arm I (blinatumomab, chemotherapy)
Experimental
See Detailed Description
干预措施: Leucovorin Calcium (Drug)
Arm II (chemotherapy)
Active Comparator
See Detailed Description
干预措施: Leucovorin Calcium (Drug)
Arm I (blinatumomab, chemotherapy)
Experimental
See Detailed Description
干预措施: Methotrexate (Drug)
Arm I (blinatumomab, chemotherapy)
Experimental
See Detailed Description
干预措施: Daunorubicin (Drug)
Arm II (chemotherapy)
Active Comparator
See Detailed Description
干预措施: Dexamethasone (Drug)
Arm II (chemotherapy)
Active Comparator
See Detailed Description
干预措施: Etoposide (Drug)
结局指标
主要结局
Overall Survival (OS) Among Patients Who Were MRD Negative After Induction and Intensification Chemotherapy
时间窗: Assessed every 3 months for 2 years, then every 6 months for 3 years, then annually for 5 years
Overall survival is defined as the time from randomization to death of any cause.
次要结局
- OS Among of Those Who Are MRD+ at Randomization and Then Convert to MRD- After 2 Cycles of Blinatumomab to Those Patients Who Are MRD- at Randomization and Remain MRD- After 2 Cycles of Blinatumomab or Consolidation Chemotherapy(Assessed every 3 months for 2 years, then every 6 months for 3 years, then annually for 5 years)
- Relapse-free Survival (RFS) Among Patients Who Were MRD Negative After Induction and Intensification Chemotherapy(Assessed every 3 months for 2 years, then every 6 months for 3 years, then annually for 5 years)
- RFS Among of Those Who Are MRD+ at Randomization and Then Convert to MRD- After 2 Cycles of Blinatumomab to Those Patients Who Are MRD- at Randomization and Remain MRD- After 2 Cycles of Blinatumomab or Consolidation Chemotherapy(Assessed every 3 months for 2 years, then every 6 months for 3 years, then annually for 5 years)
- OS Among MRD Negative Patients Who Proceed to Allogeneic Transplant on Study(Assessed every 3 months for 2 years, then every 6 months for 3 years, then annually for 5 years)
研究者
研究点 (544)
Loading locations...
相似试验
进行中（未招募）
3 期
A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic LeukemiaB Acute Lymphoblastic LeukemiaB Lymphoblastic LymphomaDown SyndromeNCT03914625National Cancer Institute (NCI)6,720
进行中（未招募）
3 期
Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic LeukemiaRecurrent B Acute Lymphoblastic LeukemiaNCT02101853National Cancer Institute (NCI)669
已完成
3 期
Study of Panitumumab Efficacy in Patients With Recurrent and/or Metastatic Head and Neck CancerRecurrent and/or Metastatic Head and Neck CancerNCT00460265Amgen658
进行中（未招募）
3 期
Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing SarcomaMetastatic Malignant Neoplasm in the Bone MarrowPeripheral Primitive Neuroectodermal Tumor of Soft TissuesMetastatic Ewing SarcomaMetastatic Malignant Neoplasm in the BoneMetastatic Malignant Neoplasm in the LungMetastatic Peripheral Primitive Neuroectodermal Tumor of BoneNCT02306161National Cancer Institute (NCI)312
进行中（未招募）
3 期
Brentuximab Vedotin and Combination Chemotherapy in Treating Children and Young Adults With Stage IIB, Stage IIIB, IVA, or IVB Hodgkin LymphomaAnn Arbor Stage IIIB Hodgkin LymphomaChildhood Hodgkin LymphomaAnn Arbor Stage IVB Hodgkin LymphomaClassic Hodgkin LymphomaAnn Arbor Stage IIB Hodgkin LymphomaAnn Arbor Stage IVA Hodgkin LymphomaNCT02166463National Cancer Institute (NCI)600
相关资讯
Real-World Study Confirms Blinatumomab Effectiveness as Bridge to Transplant in B-Cell Precursor ALL- A large European real-world study of 264 adults treated with blinatumomab found high complete remission rates of 82.0% in relapsed/refractory BCP-ALL and 81.8% MRD response in MRD-positive patients.
- Earlier blinatumomab use was associated with improved survival outcomes, with median OS of 31.7 months in first salvage versus 13.0 months in later salvage therapy.
- Over 60% of responding patients proceeded to allogeneic stem cell transplantation, with most not requiring additional anti-cancer therapy beforehand.
- The safety profile was consistent with clinical trials, with no new safety signals identified; CRS occurred in 14.4% and grade ≥3 neurologic events in 8.0% of patients.4 months agoBlinatumomab Approved for Consolidation Therapy in CD19-Positive B-ALL, Regardless of MRD Status- The FDA approved blinatumomab in June 2024 for CD19-positive, Philadelphia chromosome-negative B-ALL consolidation, expanding its use in both adult and pediatric patients.
- ECOG-ACRIN E1910 trial data supported the approval, showing superior overall survival with blinatumomab plus chemotherapy compared to chemotherapy alone.
- Blinatumomab is now a standard component of consolidation therapy, irrespective of a patient's minimal residual disease (MRD) status or backbone chemotherapy.
- Research continues to refine blinatumomab's role, exploring optimal patient selection, treatment sequencing, and the necessity of allogeneic stem cell transplant.last yearFDA Approves Blinatumomab for Early-Stage CD19-Positive B-ALL- The FDA has approved blinatumomab for adult and pediatric patients with CD19-positive, Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia (B-ALL) in the consolidation phase.
- The approval was based on the Phase 3 E1910 trial, which showed a significant improvement in overall survival when blinatumomab was added to consolidation chemotherapy.
- In the E1910 study, the 3-year OS rate was 84.8% in the blinatumomab arm compared to 69% in the chemotherapy arm (HR, 0.42; 95% CI, 0.24-0.75; P = 0.003).
- Blinatumomab's approval marks a significant advancement in the treatment of B-ALL, offering a new standard of care to reduce relapse risk and improve survival rates.2 years agoFDA Approves Blinatumomab for CD19-Positive B-ALL Consolidation Phase- The FDA has approved blinatumomab for treating CD19-positive, Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia (B-ALL) in the consolidation phase.
- The approval is supported by the Phase 3 ECOG-ACRIN E1910 study, which showed superior overall survival with blinatumomab plus chemotherapy compared to chemotherapy alone.
- Another Phase 3 study, 20120215, demonstrated that blinatumomab led to a significantly higher 5-year overall survival rate compared to intensive chemotherapy in pediatric and young adult patients.
- Blinatumomab, a Bispecific T-cell Engager (BiTE®) therapy, is now a standard of care, offering a more effective treatment option than chemotherapy alone for B-ALL patients.2 years ago